Medical News Today -
5 Nov 2013 12:00
Janssen R&D Ireland (Janssen) has announced the presentation of new data at The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC for the investigational protease inhibitor simeprevir (TMC435) in the treatment of genotype 1 chronic hepatitis C in treatment-naive and treatment-experienced adult patients with compensated liver disease...
Share this Article